EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis‐Related Biomarkers

Minxuan Shen, Qinbo Cai iD, Rongchang Wang, Feiran Zhang, Huanjie Chen, Xiaoqun Wang, Rongman Xie, Jie Zhang, Baoyi Liu, Yulong He, Xun Hou, Dongjie Yang iD

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70124 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Minxuan Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Ferroptosis, Stomach Neoplasms, Neoadjuvant Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Key Laboratory of Digestive Cancer Research, Major Clinical Technology in Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of neoadjuvant chemotherapy (NAC) combined with surgery and postoperative adjuvant chemotherapy in improving the prognosis of locally advanced gastric cancer (LAGC) has been confirmed. Nevertheless, there is still no effective tool to predict the response to NAC in gastric cancer patients.

Methods

This study included a total of 184 patients (118 in the training cohort and 66 in the testing cohort) treated with oxaliplatin + fluorouracil‐based NAC from January 2010 to July 2022. Immunohistochemistry staining of biomarkers was carried out on the endoscopy biopsy specimens before receiving treatment. Logistic regression was performed to explore the predictive biomarkers of response to NAC, and internal verification was carried out by using the bootstrap method.

Result

Ferroptosis increased significantly in NAC‐sensitive LAGC. Among the molecular markers related to ferroptosis, Fe 2+ , ACSL4, DHODH, GCH1, and FSP1 showed significant differences between the sensitive and nonsensitive groups. Logistic regression analysis revealed Fe 2+ , ACSL4, DHODH, and GCH1 as predictors of the efficacy of NAC. A nomogram prediction model was established based on identified biomarkers. The area under the ROC curve (AUC) of the nomogram model was 0.89, which indicated that the prediction results of the model were highly consistent with the actual situation (Hosmer–Lemeshow test p = 0.684). The AUC of the nomogram model in the external validation set ( N = 66) was 0.82, indicating that the model has certain predictive ability.

Conclusion

This study revealed the critical value of biomarkers related to ferroptosis serving as novel predictive biomarkers for patients with LAGC receiving NAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisStomach NeoplasmsNeoadjuvant TherapyBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedNomogramsFluorouracilChemotherapy, AdjuvantOxaliplatinTreatment OutcomePredictive Value of TestsAdult

Stichwörter der Autor:innen

ferroptosisgastric cancerneoadjuvant chemotherapyprediction model

Substanzen

Biomarkers, TumorFluorouracilOxaliplatin

Autor:innen und Institutionen

  • Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
  • Guangdong Provincial Key Laboratory of Digestive Cancer Research, Shenzhen, Guangdong, China.
  • Research Center for Diagnosis and Treatment of Gastric Cancer, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • General Surgery Laboratory, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Qinbo Cai, Dongjie Yang

Förderung

  • National Natural Science Foundation of China
  • Guangdong Provincial Key Laboratory of Digestive Cancer Research
  • Major Clinical Technology in Guangzhou
  • Research start-up fund of part-time PI, SAHSYSU
  • Funding of Shenzhen Clinical Research Center for Gastroenterology (Gastrointestinal Surgery)
  • Kelin New Star of the First Affiliated Hospital of Sun Yat-Sen University

Zitieren

APA

Shen, M., Cai, Q., Wang, R., Zhang, F., Chen, H., Wang, X., Xie, R., Zhang, J., Liu, B., He, Y., Hou, X., & Yang, D. (2025). Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis‐Related Biomarkers. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70124

Vancouver

Shen M, Cai Q, Wang R, Zhang F, Chen H, Wang X, et al. Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis‐Related Biomarkers. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70124

BibTeX
@article{Shen2025,
  author = {Shen, Minxuan and Cai, Qinbo and Wang, Rongchang and Zhang, Feiran and Chen, Huanjie and Wang, Xiaoqun and Xie, Rongman and Zhang, Jie and Liu, Baoyi and He, Yulong and Hou, Xun and Yang, Dongjie},
  title = {Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis‐Related Biomarkers},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70124}
}
Kostenlos starten →